About Rocket Pharmaceuticals, Inc.
https://rocketpharma.comRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
CEO
Gaurav D. Shah
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-01-05 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
B of A Securities
Buy
Chardan Capital
Buy
Canaccord Genuity
Buy
UBS
Buy
BMO Capital
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
MONARCH PARTNERS ASSET MANAGEMENT LLC
Shares:68.15M
Value:$269.87M
HEALTHCOR MANAGEMENT, L.P.
Shares:68.15M
Value:$269.87M
RTW INVESTMENTS, LP
Shares:17.69M
Value:$70.04M
Summary
Showing Top 3 of 207
About Rocket Pharmaceuticals, Inc.
https://rocketpharma.comRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $52.25M ▼ | $-50.33M ▲ | 0% | $-0.45 ▲ | $-46.62M ▲ |
| Q2-2025 | $0 | $71.15M ▲ | $-68.92M ▼ | 0% | $-0.62 ▼ | $-65.87M ▼ |
| Q1-2025 | $0 | $64.39M ▲ | $-61.33M ▼ | 0% | $-0.56 ▲ | $-57.87M ▼ |
| Q4-2024 | $0 | $62.69M ▼ | $-60.33M ▲ | 0% | $-0.62 ▲ | $-57.49M ▲ |
| Q3-2024 | $0 | $69.42M | $-66.72M | 0% | $-0.71 | $-63.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $222.76M ▼ | $368.03M ▼ | $54.36M ▼ | $313.67M ▼ |
| Q2-2025 | $271.49M ▼ | $420.98M ▼ | $66.77M ▲ | $354.21M ▼ |
| Q1-2025 | $318.16M ▼ | $471.07M ▼ | $58.93M ▼ | $412.14M ▼ |
| Q4-2024 | $372.34M ▲ | $527.7M ▲ | $64.47M ▲ | $463.23M ▲ |
| Q3-2024 | $235.66M | $393.69M | $63.92M | $329.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-50.33M ▲ | $-50.43M ▼ | $93.62M ▲ | $-59K ▼ | $43.13M ▲ | $-50.37M ▼ |
| Q2-2025 | $-68.92M ▼ | $-48.96M ▲ | $31.76M ▲ | $215K ▲ | $-16.99M ▲ | $-49.01M ▲ |
| Q1-2025 | $-61.33M ▼ | $-55.8M ▼ | $-58.03M ▼ | $12K ▼ | $-113.83M ▼ | $-56.17M ▼ |
| Q4-2024 | $-60.33M ▲ | $-46.96M ▲ | $-37.87M ▼ | $182.86M ▲ | $98.04M ▲ | $-47.27M ▲ |
| Q3-2024 | $-66.72M | $-52.1M | $78.92M | $176K | $26.99M | $-53.69M |
CEO
Gaurav D. Shah
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-01-05 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
B of A Securities
Buy
Chardan Capital
Buy
Canaccord Genuity
Buy
UBS
Buy
BMO Capital
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
MONARCH PARTNERS ASSET MANAGEMENT LLC
Shares:68.15M
Value:$269.87M
HEALTHCOR MANAGEMENT, L.P.
Shares:68.15M
Value:$269.87M
RTW INVESTMENTS, LP
Shares:17.69M
Value:$70.04M
Summary
Showing Top 3 of 207